AR036677A1 - Uso de aminometilcromanos sustituidos para la elaboracion de un medicamento, un procedimiento para la preparacion de estos compuestos y las composiciones farmaceuticas que contienen estos compuestos en calidad de principios activos - Google Patents
Uso de aminometilcromanos sustituidos para la elaboracion de un medicamento, un procedimiento para la preparacion de estos compuestos y las composiciones farmaceuticas que contienen estos compuestos en calidad de principios activosInfo
- Publication number
- AR036677A1 AR036677A1 ARP020103509A ARP020103509A AR036677A1 AR 036677 A1 AR036677 A1 AR 036677A1 AR P020103509 A ARP020103509 A AR P020103509A AR P020103509 A ARP020103509 A AR P020103509A AR 036677 A1 AR036677 A1 AR 036677A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compounds
- preparation
- parkinson
- syndromes
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 208000027776 Extrapyramidal disease Diseases 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 206010034010 Parkinsonism Diseases 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 2
- 229940035678 anti-parkinson drug Drugs 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000003287 optical effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- BSRHATGBRQMDRF-UHFFFAOYSA-N 3,4-dihydro-2h-chromen-2-ylmethanamine Chemical class C1=CC=C2OC(CN)CCC2=C1 BSRHATGBRQMDRF-UHFFFAOYSA-N 0.000 abstract 1
- 229940123736 Decarboxylase inhibitor Drugs 0.000 abstract 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 abstract 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 abstract 1
- 208000002033 Myoclonus Diseases 0.000 abstract 1
- 208000005793 Restless legs syndrome Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 206010044565 Tremor Diseases 0.000 abstract 1
- 208000018839 Wilson disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003954 decarboxylase inhibitor Substances 0.000 abstract 1
- 230000003291 dopaminomimetic effect Effects 0.000 abstract 1
- 230000000142 dyskinetic effect Effects 0.000 abstract 1
- 230000000632 dystonic effect Effects 0.000 abstract 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 1
- 150000004678 hydrides Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000003176 neuroleptic agent Substances 0.000 abstract 1
- 230000000701 neuroleptic effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describe el uso de aminometilcromanos sustituidos de fórmula (1) en donde R representa hidrógeno o un grupo protector de hidroxilo, y sus isómeros ópticos y sales o solvatos farmacéuticamente aceptables, para la elaboración de un medicamento destinado al tratamiento de los trastornos de movilidad extrapiramidales tales como la enfermedad de Parkinson idiopática, los síndromes de Parkinson, los síndromes discinéticos, coreáticos o distónicos, el temblor, el síndrome de Gilles de la Tourette, el balismo, el mioclono, el síndrome de las piernas inquietas o la enfermedad de Wilson. También se describe el uso de los compuestos de fórmula (1) para la elaboración de un medicamento destinado al tratamiento de los efectos adversos en los trastornos de movilidad extrapiramidales, en particular los efectos adversos dopaminomiméticos de los fármacos anti-Parkinsonianos en la enfermedad de Parkinson idiopática o los síndromes de Parkinson y/o al tratamiento de los síndromes extrapiramidales (EPS) inducidos por neurolépticos. También se describe un procedimiento para la preparación de los compuestos de fórmula (1), así como una composición farmacéutica que comprende, como principios activos, (i) un compuesto de la fórmula (1) o uno de sus isómeros ópticos y/o sales o solvatos farmacéuticamente aceptables, (ii) por lo menos un fármaco anti-Parkinsoniano y, eventualmente (iii) al menos un inhibidor de la descarboxilasa, en combinación con uno o más excipientes farmacéuticamente aceptables. El procedimiento de preparación de los compuestos de fórmula (1) que tienen una estereoquímica definida consiste en que una cromanoamina de fórmula (2) se hace reaccionar con un aldehído de la fórmula (3) y se somete a tratamiento con un dador de hidruro.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01122377 | 2001-09-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036677A1 true AR036677A1 (es) | 2004-09-29 |
Family
ID=8178662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103509A AR036677A1 (es) | 2001-09-19 | 2002-09-18 | Uso de aminometilcromanos sustituidos para la elaboracion de un medicamento, un procedimiento para la preparacion de estos compuestos y las composiciones farmaceuticas que contienen estos compuestos en calidad de principios activos |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7618988B2 (es) |
| EP (1) | EP1427724B1 (es) |
| JP (1) | JP4615857B2 (es) |
| KR (1) | KR100912911B1 (es) |
| CN (1) | CN100338060C (es) |
| AR (1) | AR036677A1 (es) |
| AT (1) | ATE325120T1 (es) |
| AU (1) | AU2002331229B2 (es) |
| BR (1) | BR0212555A (es) |
| CA (1) | CA2460696C (es) |
| CY (1) | CY1105118T1 (es) |
| DE (1) | DE60211186T2 (es) |
| DK (1) | DK1427724T3 (es) |
| ES (1) | ES2262840T3 (es) |
| HU (1) | HUP0401910A3 (es) |
| MX (1) | MXPA04002492A (es) |
| MY (1) | MY128882A (es) |
| PE (1) | PE20030428A1 (es) |
| PL (1) | PL208787B1 (es) |
| PT (1) | PT1427724E (es) |
| RU (1) | RU2322443C2 (es) |
| SI (1) | SI1427724T1 (es) |
| TW (1) | TWI244391B (es) |
| WO (1) | WO2003024960A1 (es) |
| ZA (1) | ZA200402855B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10318690B3 (de) * | 2003-04-24 | 2004-11-11 | Merck Patent Gmbh | Verfahren zur Herstellung von Nicotinaldehyden |
| CN101120002A (zh) | 2005-02-17 | 2008-02-06 | 惠氏公司 | 环烷基稠合的吲哚、苯并噻吩、苯并呋喃和茚衍生物 |
| AU2006261314B2 (en) * | 2005-06-21 | 2012-03-22 | Merck Patent Gmbh | Solid pharmaceutical preparation containing (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chroman |
| FR2978916B1 (fr) | 2011-08-10 | 2013-07-26 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
| PT2838517T (pt) * | 2012-04-18 | 2018-01-04 | Contera Pharma Aps | Formulação farmacêutica disponível sob forma oral adequada para a melhoria da gestão dos distúrbios da mobilidade |
| FR3001894A1 (fr) | 2013-02-08 | 2014-08-15 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
| CA3030089C (en) | 2016-07-11 | 2024-04-23 | Contera Pharma Aps | Pulsatile drug delivery system for treating morning akinesia |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5767132A (en) * | 1980-10-07 | 1982-04-23 | Nippon Steel Corp | Vertical type continuous annealing furnace having independently moving middle partition plate |
| DE4135474A1 (de) * | 1991-10-28 | 1993-04-29 | Bayer Ag | 2-aminomethyl-chromane |
| SI9300097B (en) * | 1992-02-27 | 2001-12-31 | Janssen Pharmaceutica Nv | (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines |
| DE69433401T2 (de) * | 1993-08-19 | 2004-09-16 | Janssen Pharmaceutica N.V. | Gefässverengende dihydrobenzopyranderivate |
| PT707007E (pt) * | 1994-10-14 | 2002-06-28 | Merck Patent Gmbh | Derivados amino(tio)eter como agentes activos no snc |
| US5585388A (en) * | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| PT874849E (pt) * | 1995-12-21 | 2002-01-30 | Pfizer | Derivados octa-hidro-pirrolo¬1,2-a|pirazina 2,7-substituidos |
| US5756521A (en) * | 1996-04-03 | 1998-05-26 | American Home Products Corporation | Chroman-2-ylmethylamino derivatives |
| UA73981C2 (en) * | 2000-03-10 | 2005-10-17 | Merck Patent Gmbh | (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit |
-
2002
- 2002-08-12 AU AU2002331229A patent/AU2002331229B2/en not_active Ceased
- 2002-08-12 HU HU0401910A patent/HUP0401910A3/hu unknown
- 2002-08-12 PL PL369684A patent/PL208787B1/pl not_active IP Right Cessation
- 2002-08-12 CA CA2460696A patent/CA2460696C/en not_active Expired - Fee Related
- 2002-08-12 EP EP02767363A patent/EP1427724B1/en not_active Expired - Lifetime
- 2002-08-12 DK DK02767363T patent/DK1427724T3/da active
- 2002-08-12 RU RU2004112190/15A patent/RU2322443C2/ru not_active IP Right Cessation
- 2002-08-12 KR KR1020047002484A patent/KR100912911B1/ko not_active Expired - Fee Related
- 2002-08-12 CN CNB028183266A patent/CN100338060C/zh not_active Expired - Fee Related
- 2002-08-12 MX MXPA04002492A patent/MXPA04002492A/es active IP Right Grant
- 2002-08-12 PT PT02767363T patent/PT1427724E/pt unknown
- 2002-08-12 SI SI200230351T patent/SI1427724T1/sl unknown
- 2002-08-12 US US10/489,960 patent/US7618988B2/en not_active Expired - Fee Related
- 2002-08-12 DE DE60211186T patent/DE60211186T2/de not_active Expired - Lifetime
- 2002-08-12 WO PCT/EP2002/009001 patent/WO2003024960A1/en not_active Ceased
- 2002-08-12 AT AT02767363T patent/ATE325120T1/de active
- 2002-08-12 BR BR0212555-2A patent/BR0212555A/pt not_active IP Right Cessation
- 2002-08-12 JP JP2003528807A patent/JP4615857B2/ja not_active Expired - Fee Related
- 2002-08-12 ES ES02767363T patent/ES2262840T3/es not_active Expired - Lifetime
- 2002-08-13 TW TW091118183A patent/TWI244391B/zh not_active IP Right Cessation
- 2002-09-16 MY MYPI20023438A patent/MY128882A/en unknown
- 2002-09-17 PE PE2002000915A patent/PE20030428A1/es not_active Application Discontinuation
- 2002-09-18 AR ARP020103509A patent/AR036677A1/es unknown
-
2004
- 2004-04-15 ZA ZA200402855A patent/ZA200402855B/en unknown
-
2006
- 2006-07-28 CY CY20061101061T patent/CY1105118T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024004846A (es) | Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo. | |
| CO2026005655A2 (es) | Inhibidor de pan-kras y uso del mismo en medicinas | |
| ECSP077185A (es) | Derivados de piridina | |
| AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
| PA8547701A1 (es) | Nucleosidos 4 substituidos. | |
| DE60034240D1 (de) | Drogen zur behandlung maligner tumoren | |
| AR079208A2 (es) | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica | |
| UY27592A1 (es) | Nuevo uso | |
| ZA202400988B (en) | Aak1 inhibitor and use thereof | |
| CO2024015820A2 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| BRPI0418004A (pt) | composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis, métodos para tratar ou prevenir condições hiperlipidêmicas, aterosclerose, mal de alzheimer, e tumores associados com colesterol, formulação farmacêutica, combinação, e, processo para preparar um composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis | |
| CO2024015816A2 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| CL2004000848A1 (es) | Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras | |
| AR034120A1 (es) | Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico | |
| UY27700A1 (es) | Compuestos oxo - azabiclícos. | |
| AR034396A1 (es) | Compuestos 4-(1r-4-piperidilen)-4h-benzo[4,5]ciclohepta[1,2]-tiofeno-1-a y sus isomeros opticamente activos, un metodo para su sintesis y el uso de dichos compuestos para la manufactura de un medicamento | |
| NO304113B1 (no) | Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament | |
| UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
| ZA202402086B (en) | Prodrug of pyrrolidone derivatives as glucokinase activator | |
| JOP20240262A1 (ar) | المركبات المحتوية على البورون العطري ونظائر الأنسولين ذات الصلة | |
| UY28979A1 (es) | Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3 | |
| CO2025015601A2 (es) | Alcoholes y éteres bicíclicos 5,6-condensados y 6,6-condensados y composiciones para su uso como moduladores de la 15-prostaglandina deshidrogenasa | |
| AR047469A1 (es) | Conservantes antimicrobianos para lograr una formulacion de dosis multiples usando ciclodextrinas beta para formas de dosificacion liquidas | |
| DOP2025000235A (es) | Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo | |
| ES2059130T3 (es) | Composiciones farmaceuticas que contienen ipriflavona, procedimiento para su preparacion y uso terapeutico relacionado. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |